PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Rigel Pharmaceuticals, Inc. (RIGL)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US7665596034

CUSIP

766559603

Sector

Healthcare

IPO Date

Nov 29, 2000

Highlights

Market Cap

$301.06M

EPS (TTM)

$0.99

PE Ratio

17.02

PEG Ratio

-0.10

Total Revenue (TTM)

$149.74M

Gross Profit (TTM)

$133.12M

EBITDA (TTM)

$33.93M

Year Range

$7.48 - $29.82

Target Price

$33.67

Short %

10.32%

Short Ratio

6.90

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
RIGL vs. APP RIGL vs. SPY
Popular comparisons:
RIGL vs. APP RIGL vs. SPY

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Rigel Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%0.00%100.00%200.00%300.00%400.00%NovemberDecember2025FebruaryMarchApril
-97.37%
293.66%
RIGL (Rigel Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Returns By Period

Rigel Pharmaceuticals, Inc. had a return of 0.18% year-to-date (YTD) and 51.80% in the last 12 months. Over the past 10 years, Rigel Pharmaceuticals, Inc. had an annualized return of -8.64%, while the S&P 500 had an annualized return of 9.68%, indicating that Rigel Pharmaceuticals, Inc. did not perform as well as the benchmark.


RIGL

YTD

0.18%

1M

-17.12%

6M

11.29%

1Y

51.80%

5Y*

0.30%

10Y*

-8.64%

^GSPC (Benchmark)

YTD

-10.18%

1M

-5.91%

6M

-9.57%

1Y

5.19%

5Y*

12.98%

10Y*

9.68%

*Annualized

Monthly Returns

The table below presents the monthly returns of RIGL, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202528.72%6.51%-21.99%-6.34%0.18%
2024-19.31%29.91%-2.63%-29.05%-6.88%-15.93%28.71%27.03%20.39%-15.76%102.57%-39.08%16.00%
20239.33%-7.93%-12.58%-14.39%23.89%-7.86%6.98%-17.39%-5.26%-25.25%41.21%27.19%-3.33%
2022-3.40%-1.95%19.12%-21.07%-23.31%-37.57%5.31%19.33%-16.90%-38.25%-7.82%123.35%-43.40%
20214.00%14.01%-17.59%8.77%-0.00%16.67%-7.83%-5.00%-4.47%-7.44%-20.54%-0.75%-24.29%
20205.61%-6.19%-26.42%14.74%9.22%-6.39%25.68%8.26%-3.61%3.33%22.18%15.51%63.55%
2019-6.09%1.39%17.35%-13.23%-4.48%22.54%-12.64%-25.88%10.65%9.63%9.27%-4.46%-6.96%
20183.09%-6.00%-5.85%1.98%-9.97%-12.92%-0.35%20.92%-5.87%-10.59%-1.39%-18.73%-40.72%
2017-12.61%17.79%35.10%-9.67%-23.41%19.21%-13.19%7.59%-0.39%47.64%10.93%-6.73%63.03%
2016-9.24%-17.45%-8.37%36.06%-8.83%-13.57%2.69%47.16%8.90%-29.16%0.00%-8.46%-21.45%
2015-8.81%44.44%19.40%19.33%-18.08%-8.02%-7.17%0.67%-17.67%2.83%29.13%-7.62%33.48%
20146.32%13.53%12.79%-17.53%2.81%10.33%-9.92%-20.49%-25.38%2.06%8.08%6.07%-20.35%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

With an overall rank of 76, RIGL is among the top 24% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of RIGL is 7676
Overall Rank
The Sharpe Ratio Rank of RIGL is 7575
Sharpe Ratio Rank
The Sortino Ratio Rank of RIGL is 8080
Sortino Ratio Rank
The Omega Ratio Rank of RIGL is 7676
Omega Ratio Rank
The Calmar Ratio Rank of RIGL is 7474
Calmar Ratio Rank
The Martin Ratio Rank of RIGL is 7676
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Rigel Pharmaceuticals, Inc. (RIGL) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for RIGL, currently valued at 0.55, compared to the broader market-2.00-1.000.001.002.003.00
RIGL: 0.55
^GSPC: 0.24
The chart of Sortino ratio for RIGL, currently valued at 1.51, compared to the broader market-6.00-4.00-2.000.002.004.00
RIGL: 1.51
^GSPC: 0.47
The chart of Omega ratio for RIGL, currently valued at 1.18, compared to the broader market0.501.001.502.00
RIGL: 1.18
^GSPC: 1.07
The chart of Calmar ratio for RIGL, currently valued at 0.48, compared to the broader market0.001.002.003.004.00
RIGL: 0.48
^GSPC: 0.24
The chart of Martin ratio for RIGL, currently valued at 2.15, compared to the broader market-5.000.005.0010.0015.0020.00
RIGL: 2.15
^GSPC: 1.08

The current Rigel Pharmaceuticals, Inc. Sharpe ratio is 0.55. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Rigel Pharmaceuticals, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio0.001.002.003.00NovemberDecember2025FebruaryMarchApril
0.55
0.24
RIGL (Rigel Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Rigel Pharmaceuticals, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2025FebruaryMarchApril
-98.42%
-14.02%
RIGL (Rigel Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Rigel Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Rigel Pharmaceuticals, Inc. was 99.37%, occurring on Nov 9, 2022. The portfolio has not yet recovered.

The current Rigel Pharmaceuticals, Inc. drawdown is 98.42%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.37%Jan 4, 20015498Nov 9, 2022
-20.57%Dec 13, 20006Dec 20, 20004Dec 27, 200010
-5.28%Dec 6, 20002Dec 7, 20002Dec 11, 20004
-0.66%Nov 30, 20001Nov 30, 20001Dec 1, 20002

Volatility

Volatility Chart

The current Rigel Pharmaceuticals, Inc. volatility is 16.54%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%NovemberDecember2025FebruaryMarchApril
16.54%
13.60%
RIGL (Rigel Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Rigel Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Rigel Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PE Ratio
20.040.060.080.0100.0
RIGL: 17.0
The chart displays the Price-to-Earnings (P/E) ratio for RIGL, comparing it with other companies in the Biotechnology industry. Currently, RIGL has a P/E ratio of 17.0. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
2.04.06.08.010.0
RIGL: -0.1
The chart shows the Price/Earnings to Growth (PEG) ratio for RIGL compared to other companies in the Biotechnology industry. RIGL currently has a PEG ratio of -0.1. This PEG ratio is negative, which typically signals that the company's earnings are expected to decline. A negative PEG is not considered meaningful for valuation purposes.
PS Ratio
2.04.06.08.010.0
RIGL: 1.7
This chart shows the Price-to-Sales (P/S) ratio for RIGL relative to other companies in the Biotechnology industry. Currently, RIGL has a P/S ratio of 1.7. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
2.04.06.08.010.0
RIGL: 89.6
The chart illustrates the Price-to-Book (P/B) ratio for RIGL in comparison with other companies in the Biotechnology industry. Currently, RIGL has a P/B value of 89.6. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Rigel Pharmaceuticals, Inc..


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab